共 219 条
[1]
January CT(2019)2019 AHA/ACC/HRS focused update of the 2014 AHA/ACC/HRS guideline for the Management of Patients with Atrial Fibrillation: a report of the American College of Cardiology/American Heart Association task force on clinical practice guidelines and the Heart Rhythm Society in collaboration with the Society of Thoracic Surgeons Circulation 140 e125-e151
[2]
Wann LS(2014)Comparison of the efficacy and safety of new oral anticoagulants with warfarin in patients with atrial fibrillation: a meta-analysis of randomised trials Lancet 383 955-962
[3]
Calkins H(2019)Comparison of the New Oral Anticoagulants and Warfarin in Patients with Atrial Fibrillation and Valvular Heart Disease: Systematic Review and Meta-Analysis Drugs R D 19 117-126
[4]
Chen LY(2018)Pharmacokinetics of new oral anticoagulants: implications for use in routine care Expert Opin Drug Metab Toxicol 14 1057-1069
[5]
Cigarroa JE(2013)Edoxaban versus warfarin in patients with atrial fibrillation N Engl J Med 369 2093-2104
[6]
Cleveland JC(2011)Rivaroxaban versus warfarin in Nonvalvular atrial fibrillation N Engl J Med 365 883-891
[7]
Ruff CT(2009)Dabigatran versus warfarin in patients with atrial fibrillation N Engl J Med 361 1139-1151
[8]
Giugliano RP(2011)Apixaban versus warfarin in patients with atrial fibrillation N Engl J Med 365 981-992
[9]
Braunwald E(2016)Use of the direct oral anticoagulants in obese patients: guidance from the SSC of the ISTH J Thromb Haemost 14 1308-1313
[10]
Hoffman EB(2012)Dabigatran is effective with a favourable safety profile in normal and overweight patients undergoing major orthopaedic surgery: a pooled analysis Thromb Res 130 818-820